371 related articles for article (PubMed ID: 36179604)
1. The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook.
Zhou Z; Hu Y; Wu Y; Qi Q; Wang J; Chen L; Wang F
Mol Immunol; 2022 Nov; 151():218-230. PubMed ID: 36179604
[TBL] [Abstract][Full Text] [Related]
2. Emerging Role of Cancer-Associated Fibroblasts in Progression and Treatment of Hepatocellular Carcinoma.
Akkız H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835352
[TBL] [Abstract][Full Text] [Related]
3. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities.
Lu C; Rong D; Zhang B; Zheng W; Wang X; Chen Z; Tang W
Mol Cancer; 2019 Aug; 18(1):130. PubMed ID: 31464625
[TBL] [Abstract][Full Text] [Related]
4. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma.
Yin Z; Dong C; Jiang K; Xu Z; Li R; Guo K; Shao S; Wang L
J Hematol Oncol; 2019 Sep; 12(1):101. PubMed ID: 31547836
[TBL] [Abstract][Full Text] [Related]
6. Macrophages as Targets in Hepatocellular Carcinoma Therapy.
Liu YT; Mao ZW; Ding Y; Wang WL
Mol Cancer Ther; 2024 Jun; 23(6):780-790. PubMed ID: 38310642
[TBL] [Abstract][Full Text] [Related]
7. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
8. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
9.
Lurje I; Werner W; Mohr R; Roderburg C; Tacke F; Hammerich L
Front Immunol; 2021; 12():650486. PubMed ID: 34025657
[TBL] [Abstract][Full Text] [Related]
10. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
11. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of Birc5 as a novel activated cell cycle program biomarker associated with infiltration of immunosuppressive myeloid-derived suppressor cells in hepatocellular carcinoma.
Liu Y; Chen X; Luo W; Zhao Y; Nashan B; Huang L; Yuan X
Cancer Med; 2023 Aug; 12(15):16370-16385. PubMed ID: 37326143
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated macrophages in liver cancer: From mechanisms to therapy.
Cheng K; Cai N; Zhu J; Yang X; Liang H; Zhang W
Cancer Commun (Lond); 2022 Nov; 42(11):1112-1140. PubMed ID: 36069342
[TBL] [Abstract][Full Text] [Related]
14. Cancer‑associated fibroblast‑induced M2‑polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor‑1 pathway.
Chen S; Morine Y; Tokuda K; Yamada S; Saito Y; Nishi M; Ikemoto T; Shimada M
Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195849
[TBL] [Abstract][Full Text] [Related]
15. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
16. [Hepatocellular Carcinoma-Derived Exosomes: Key Players in Intercellular Communication Within the Tumor Microenvironment].
Feng T; Yang X; Wang Q; Liu X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2024 Jan; 55(1):6-12. PubMed ID: 38322525
[TBL] [Abstract][Full Text] [Related]
17. Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma.
Xu Y; Liao W; Luo Q; Yang D; Pan M
Front Immunol; 2022; 13():761046. PubMed ID: 35145517
[TBL] [Abstract][Full Text] [Related]
18. Unveiling the Yin-Yang Balance of M1 and M2 Macrophages in Hepatocellular Carcinoma: Role of Exosomes in Tumor Microenvironment and Immune Modulation.
Papadakos SP; Machairas N; Stergiou IE; Arvanitakis K; Germanidis G; Frampton AE; Theocharis S
Cells; 2023 Aug; 12(16):. PubMed ID: 37626849
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma.
Sung PS
Clin Mol Hepatol; 2022 Jul; 28(3):333-350. PubMed ID: 34665953
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblasts induce immunotherapy resistance in hepatocellular carcinoma animal model.
Yu L; Liu Q; Huo J; Wei F; Guo W
Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):36-40. PubMed ID: 32415924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
